Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $70.00 at HC Wainwright

Pacira BioSciences (NASDAQ:PCRX) had its price target lifted by analysts at HC Wainwright from $57.00 to $70.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 175.81% from the company’s current price.

A number of other analysts have also commented on PCRX. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays lowered their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Trading Down 0.4 %

PCRX opened at $25.38 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -12.50 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $31.67. The firm’s fifty day simple moving average is $23.06 and its 200 day simple moving average is $18.50.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently added to or reduced their stakes in PCRX. State of Wyoming lifted its stake in Pacira BioSciences by 8.0% in the fourth quarter. State of Wyoming now owns 6,566 shares of the company’s stock valued at $124,000 after acquiring an additional 487 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after purchasing an additional 794 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.